PROGENICS PHARMACEUTICALS IN - COM (PGNX)

CUSIP: 743187106

Q1 2017 13F Holders as of 31 Mar 2017

Type / Class
Equity / COM
Total 13F shares
64,792,905
Share change
+10,372,360
Total reported value
$611,547,902
Put/Call ratio
59%
Price per share
$9.44
Number of holders
154
Value change
+$98,244,077
Number of buys
94
Number of sells
51

Quarterly Holders Quick Answers

What is CUSIP 743187106?
CUSIP 743187106 identifies PGNX - PROGENICS PHARMACEUTICALS IN - COM in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Institutional Holders of PROGENICS PHARMACEUTICALS IN - COM (PGNX) as of Q1 2017

As of 31 Mar 2017, PROGENICS PHARMACEUTICALS IN - COM (PGNX) was held by 154 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 64,792,905 shares. The largest 10 holders included FEDERATED INVESTORS INC /PA/, BlackRock Inc., VANGUARD GROUP INC, BAKER BROS. ADVISORS LP, FMR LLC, EAGLE ASSET MANAGEMENT INC, STATE STREET CORP, PINNACLE ASSOCIATES LTD, Park West Asset Management LLC, and Broadfin Capital, LLC. This page lists 154 institutional shareholders reporting positions in this security for the Q1 2017 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.